<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459873</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>A CRISPR-Cas13b System Degrades SARS-CoV and SARS-CoV-2 RNA In Vitro.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1539</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101539</ELocationID><Abstract><AbstractText>In a time of climate change, population growth, and globalization, the risk of viral spread has significantly increased. The 21st century has already witnessed outbreaks of Severe Acute Respiratory Syndrome virus (SARS-CoV), Severe Acute Respiratory Syndrome virus 2 (SARS-CoV-2), Ebola virus and Influenza virus, among others. Viruses rapidly adapt and evade human immune systems, complicating the development of effective antiviral countermeasures. Consequently, the need for novel antivirals resilient to viral mutations is urgent. In this study, we developed a CRISPR-Cas13b system to target SARS-CoV-2. Interestingly, this system was also efficient against SARS-CoV, demonstrating broad-spectrum potential. Our findings highlight CRISPR-Cas13b as a promising tool for antiviral therapeutics, underscoring its potential in RNA-virus-associated pandemic responses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Klara</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azatyan</LastName><ForeName>Ani</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8596-4313</Identifier><AffiliationInfo><Affiliation>Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ekenberg</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Güçlüler</LastName><ForeName>Gözde</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sardon Puig</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puumalainen</LastName><ForeName>Marjo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pramer</LastName><ForeName>Theodor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biomedrex Genetics, Alfred Nobels allé 8, 14152 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monteil</LastName><ForeName>Vanessa M</ForeName><Initials>VM</Initials><Identifier Source="ORCID">0000-0002-2652-5695</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Agency of Sweden, 17182 Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirazimi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Agency of Sweden, 17182 Solna, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Veterinary Institute, 75189 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FS-2022:0010</GrantID><Agency>Karolinska Institutet</Agency><Country /></Grant><Grant><GrantID>ID21-0086</GrantID><Agency>Stiftelsen för Strategisk Forskning</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="Y">CRISPR-Cas Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="Y">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="Y">Severe acute respiratory syndrome-related coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRISPR-Cas13b</Keyword><Keyword MajorTopicYN="N">SARS-CoV</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral development</Keyword></KeywordList><CoiStatement>T.P. is the CEO of Biomedrex Genetics. M.P., A.A., M.E., G.G., and L.S.P. are employed by Biomedrex Genetics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459873</ArticleId><ArticleId IdType="pmc">PMC11512209</ArticleId><ArticleId IdType="doi">10.3390/v16101539</ArticleId><ArticleId IdType="pii">v16101539</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carrasco-Hernandez R., Jácome R., Vidal Y.L., de León S.P. Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review. ILAR J. 2017;58:343–358. doi: 10.1093/ilar/ilx026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ilar/ilx026</ArticleId><ArticleId IdType="pmc">PMC7108571</ArticleId><ArticleId IdType="pubmed">28985316</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J., Sun J., Li D., Wang N., Wang L., Zhang C., Meng X., Ji X., Suchard M.A., Zhang X., et al. Emerging viruses: Cross-species transmission of coronaviruses, filoviruses, henipaviruses, and rotaviruses from bats. Cell Rep. 2022;39:110969. doi: 10.1016/j.celrep.2022.110969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110969</ArticleId><ArticleId IdType="pmc">PMC9148931</ArticleId><ArticleId IdType="pubmed">35679864</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G., Liu Z., Chen D. Human coronaviruses: Origin, host and receptor. J. Clin. Virol. 2022;155:105246. doi: 10.1016/j.jcv.2022.105246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105246</ArticleId><ArticleId IdType="pmc">PMC9301904</ArticleId><ArticleId IdType="pubmed">35930858</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoullough L.C., Fareh M., Hu W., Sozzi V., Makhlouf C., Droungas Y., Lee C.L., Takawy M., Fabb S.A., Payne T.J., et al. CRISPR-Cas13b-mediated suppression of HBV replication and protein expression. J. Hepatol. 2024 doi: 10.1016/j.jhep.2024.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2024.05.025</ArticleId><ArticleId IdType="pubmed">38815932</ArticleId></ArticleIdList></Reference><Reference><Citation>Fareh M., Zhao W., Hu W., Casan J.M.L., Kumar A., Symons J., Zerbato J.M., Fong D., Voskoboinik I., Ekert P.G., et al. Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance. Nat. Commun. 2021;12:4270. doi: 10.1038/s41467-021-24577-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24577-9</ArticleId><ArticleId IdType="pmc">PMC8277810</ArticleId><ArticleId IdType="pubmed">34257311</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng L., Liu Y., Nguyenla X.H., Abbott T.R., Han M., Zhu Y., Chemparathy A., Lin X., Chen X., Wang H., et al. Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro. Nat. Commun. 2022;13:2766. doi: 10.1038/s41467-022-30546-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30546-7</ArticleId><ArticleId IdType="pmc">PMC9119983</ArticleId><ArticleId IdType="pubmed">35589813</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Gao X., Kan C., Li L., Zhang Y., Gao Y., Zhang S., Zhou L., Zhao H., Li M., et al. CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection. Medcomm. 2023;4:e208. doi: 10.1002/mco2.208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.208</ArticleId><ArticleId IdType="pmc">PMC9887993</ArticleId><ArticleId IdType="pubmed">36744219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H., Wilson H., Jayakumar S., Kulkarni V., Kulkarni S. Efficient Inhibition of HIV Using CRISPR/Cas13d Nuclease System. Viruses. 2021;13:1850. doi: 10.3390/v13091850.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13091850</ArticleId><ArticleId IdType="pmc">PMC8473377</ArticleId><ArticleId IdType="pubmed">34578431</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong H., Huang J., Xiao Q., He B., Dong X., Liu Y., Yang X., Han D., Wang Z., Wang X., et al. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects. Nat. Biotechnol. 2022;41:108–119. doi: 10.1038/s41587-022-01419-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-022-01419-7</ArticleId><ArticleId IdType="pubmed">35953673</ArticleId></ArticleIdList></Reference><Reference><Citation>Abudayyeh O.O., Gootenberg J.S., Essletzbichler P., Han S., Joung J., Belanto J.J., Verdine V., Cox D.B.T., Kellner M.J., Regev A., et al. RNA targeting with CRISPR–Cas13. Nature. 2017;550:280–284. doi: 10.1038/nature24049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24049</ArticleId><ArticleId IdType="pmc">PMC5706658</ArticleId><ArticleId IdType="pubmed">28976959</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Jing P., Zhou Y., Zhang J., Shi J., Zhang M., Yang H., Fei J. The effects of length and sequence of gRNA on Cas13b and Cas13d activity in vitro and in vivo. Biotechnol. J. 2023;18:e2300002. doi: 10.1002/biot.202300002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biot.202300002</ArticleId><ArticleId IdType="pubmed">37148478</ArticleId></ArticleIdList></Reference><Reference><Citation>Méndez-Mancilla A., Wessels H.-H., Legut M., Kadina A., Mabuchi M., Walker J., Robb G.B., Holden K., Sanjana N.E. Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells. Cell Chem. Biol. 2021;29:321–327.e4. doi: 10.1016/j.chembiol.2021.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2021.07.011</ArticleId><ArticleId IdType="pmc">PMC8792099</ArticleId><ArticleId IdType="pubmed">34343484</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels H.H., Méndez-Mancilla A., Hao Y., Papalexi E., Mauck W.M., III, Lu L., Morris J.A., Mimitou E.P., Smibert P., Sanjana N.E., et al. Efficient combinatorial targeting of RNA tran-scripts in single cells with Cas13 RNA Perturb-seq. Nat. Methods. 2023;20:86–94. doi: 10.1038/s41592-022-01705-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-022-01705-x</ArticleId><ArticleId IdType="pmc">PMC10030154</ArticleId><ArticleId IdType="pubmed">36550277</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang B., Zhang J., Schwoerer M.P., Nelson A.N., Schoeman E., Guo A., Ploss A., Myhrvold C. Highly multiplexed mRNA quantitation with CRISPR-Cas13. bioRxiv. 2023 doi: 10.1101/2023.08.16.553527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.08.16.553527</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels H.-H., Méndez-Mancilla A., Guo X., Legut M., Daniloski Z., Sanjana N.E. Massively parallel Cas13 screens reveal principles for guide RNA design. Nat. Biotechnol. 2020;38:722–727. doi: 10.1038/s41587-020-0456-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0456-9</ArticleId><ArticleId IdType="pmc">PMC7294996</ArticleId><ArticleId IdType="pubmed">32518401</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott T.R., Dhamdhere G., Liu Y., Lin X., Goudy L., Zeng L., Chemparathy A., Chmura S., Heaton N.S., Debs R., et al. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. Cell. 2020;181:865–876.e12. doi: 10.1016/j.cell.2020.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.020</ArticleId><ArticleId IdType="pmc">PMC7189862</ArticleId><ArticleId IdType="pubmed">32353252</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J., Techakriengkrai N., Nedumpun T., Suradhat S. Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells. Sci. Rep. 2020;10:9617. doi: 10.1038/s41598-020-66775-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-66775-3</ArticleId><ArticleId IdType="pmc">PMC7295971</ArticleId><ArticleId IdType="pubmed">32541822</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox D.B.T., Gootenberg J.S., Abudayyeh O.O., Franklin B., Kellner M.J., Joung J., Zhang F. RNA editing with CRISPR-Cas13. Science. 2017;358:1019–1027. doi: 10.1126/science.aaq0180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaq0180</ArticleId><ArticleId IdType="pmc">PMC5793859</ArticleId><ArticleId IdType="pubmed">29070703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Zhang X., Cheng L., Luo Y. An overview and metanalysis of machine and deep learning-based CRISPR gRNA design tools. RNA Biol. 2019;17:13–22. doi: 10.1080/15476286.2019.1669406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476286.2019.1669406</ArticleId><ArticleId IdType="pmc">PMC6948960</ArticleId><ArticleId IdType="pubmed">31533522</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandaru S., Tsuji M.H., Shimizu Y., Usami K., Lee S., Takei N.K., Yoshitome K., Nishimura Y., Otsuki T., Ito T. Structure-based design of gRNA for Cas13. Sci. Rep. 2020;10:11610. doi: 10.1038/s41598-020-68459-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-68459-4</ArticleId><ArticleId IdType="pmc">PMC7360764</ArticleId><ArticleId IdType="pubmed">32665590</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagchi R., Tinker-Kulberg R., Salehin M., Supakar T., Chamberlain S., Ligaba-Osena A., Josephs E.A. Polyvalent guide RNAs for CRISPR antivirals. iScience. 2022;25:105333. doi: 10.1016/j.isci.2022.105333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.105333</ArticleId><ArticleId IdType="pmc">PMC9618770</ArticleId><ArticleId IdType="pubmed">36325075</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X., Liu Y., Chemparathy A., Pande T., La Russa M., Qi L.S. A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses. Cell Rep. Med. 2021;2:100245. doi: 10.1016/j.xcrm.2021.100245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100245</ArticleId><ArticleId IdType="pmc">PMC7985958</ArticleId><ArticleId IdType="pubmed">33778788</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X., Rahman J.A., Wessels H.-H., Méndez-Mancilla A., Haro D., Chen X., Sanjana N.E. Transcriptome-wide Cas13 guide RNA design for model organisms and viral RNA pathogens. Cell Genom. 2021;1:100001. doi: 10.1016/j.xgen.2021.100001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xgen.2021.100001</ArticleId><ArticleId IdType="pmc">PMC9164475</ArticleId><ArticleId IdType="pubmed">35664829</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu D., Han H.-J., Yu J., Kim J., Lee G.-H., Yang J.-H., Song B.-M., Tark D., Choi B.-S., Kang S.-M., et al. Pseudoknot-targeting Cas13b combats SARS-CoV-2 infection by suppressing viral replication. Mol. Ther. 2023;31:1675–1687. doi: 10.1016/j.ymthe.2023.03.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2023.03.018</ArticleId><ArticleId IdType="pmc">PMC10028249</ArticleId><ArticleId IdType="pubmed">36945774</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F.-W., Kok K.-H., Zhu Z., Chu H., To K.K.-W., Yuan S., Yuen K.-Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 2020;9:221–236. doi: 10.1080/22221751.2020.1719902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1719902</ArticleId><ArticleId IdType="pmc">PMC7067204</ArticleId><ArticleId IdType="pubmed">31987001</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelrahman Z., Li M., Wang X. Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. Front. Immunol. 2020;11:552909. doi: 10.3389/fimmu.2020.552909.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.552909</ArticleId><ArticleId IdType="pmc">PMC7516028</ArticleId><ArticleId IdType="pubmed">33013925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N., Sharma S., Kumar R., Tripathi B.N., Barua S., Ly H., Rouse B.T. Host-Directed Antiviral Therapy. Clin. Microbiol. Rev. 2020;33:e00168-19. doi: 10.1128/CMR.00168-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00168-19</ArticleId><ArticleId IdType="pmc">PMC7227448</ArticleId><ArticleId IdType="pubmed">32404434</ArticleId></ArticleIdList></Reference><Reference><Citation>Geraghty R.J., Aliota M.T., Bonnac L.F. Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. Viruses. 2021;13:667. doi: 10.3390/v13040667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13040667</ArticleId><ArticleId IdType="pmc">PMC8069527</ArticleId><ArticleId IdType="pubmed">33924302</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamzeeva P.N., Aralov A.V., Alferova V.A., Korshun V.A. Recent Advances in Molecular Mechanisms of Nucleoside Antivirals. Curr. Issues Mol. Biol. 2023;45:6851–6879. doi: 10.3390/cimb45080433.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cimb45080433</ArticleId><ArticleId IdType="pmc">PMC10453654</ArticleId><ArticleId IdType="pubmed">37623252</ArticleId></ArticleIdList></Reference><Reference><Citation>Freije C.A., Myhrvold C., Boehm C.K., Lin A.E., Welch N.L., Carter A., Metsky H.C., Luo C.Y., Abudayyeh O.O., Gootenberg J.S., et al. Programmable Inhibition and Detection of RNA Viruses Using Cas13. Mol. Cell. 2019;76:826–837.e11. doi: 10.1016/j.molcel.2019.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2019.09.013</ArticleId><ArticleId IdType="pmc">PMC7422627</ArticleId><ArticleId IdType="pubmed">31607545</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves L.C.S., Orr-Burks N., Vanover D., Mosur V.V., Hosking S.R., Kumar E. K. P., Jeong H., Jung Y., Assumpção J.A.F., Peck H.E., et al. mRNA-encoded Cas13 treatment of Influenza via site-specific degradation of genomic RNA. PLoS Pathog. 2024;20:e1012345. doi: 10.1371/journal.ppat.1012345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1012345</ArticleId><ArticleId IdType="pmc">PMC11253931</ArticleId><ArticleId IdType="pubmed">38968329</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard E.L., Vanover D., Bawage S.S., Tiwari P.M., Rotolo L., Beyersdorf J., Peck H.E., Bruno N.C., Hincapie R., Michel F., et al. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents. Nat. Biotechnol. 2021;39:717–726. doi: 10.1038/s41587-021-00822-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-00822-w</ArticleId><ArticleId IdType="pubmed">33536629</ArticleId></ArticleIdList></Reference><Reference><Citation>Konermann S., Lotfy P., Brideau N.J., Oki J., Shokhirev M.N., Hsu P.D. Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. Cell. 2018;173:665–676.e14. doi: 10.1016/j.cell.2018.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.02.033</ArticleId><ArticleId IdType="pmc">PMC5910255</ArticleId><ArticleId IdType="pubmed">29551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuillet V., Canard B., Trautmann A. Combining Antivirals and Immunomodulators to Fight COVID-19. Trends Immunol. 2020;42:31–44. doi: 10.1016/j.it.2020.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.11.003</ArticleId><ArticleId IdType="pmc">PMC7664349</ArticleId><ArticleId IdType="pubmed">33281063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W., Kumar A., Ahmed S.F., Qi S., Ma D.K.G., Chen H., Singh G.J., Casan J.M.L., Haber M., Voskoboinik I., et al. Single-base tiled screen unveils design principles of PspCas13b for potent and off-target-free RNA silencing. Nat. Struct. Mol. Biol. 2024 doi: 10.1038/s41594-024-01336-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-024-01336-0</ArticleId><ArticleId IdType="pubmed">38951623</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W., Zheng Y., Zeng X., He B., Cheng W. Structural biology of SARS-CoV-2: Open the door for novel therapies. Signal Transduct. Target. Ther. 2022;7:26. doi: 10.1038/s41392-022-00884-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00884-5</ArticleId><ArticleId IdType="pmc">PMC8793099</ArticleId><ArticleId IdType="pubmed">35087058</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam J., Islam N.N., Alom S., Kabir M., Halim M.A. A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites. Immunobiology. 2022;228:152302. doi: 10.1016/j.imbio.2022.152302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2022.152302</ArticleId><ArticleId IdType="pmc">PMC9663145</ArticleId><ArticleId IdType="pubmed">36434912</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannalire R., Cerchia C., Beccari A.R., Di Leva F.S., Summa V. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. J. Med. Chem. 2020;65:2716–2746. doi: 10.1021/acs.jmedchem.0c01140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01140</ArticleId><ArticleId IdType="pmc">PMC7688049</ArticleId><ArticleId IdType="pubmed">33186044</ArticleId></ArticleIdList></Reference><Reference><Citation>Báez-Santos Y.M., John S.E., Mesecar A.D. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral. Res. 2015;115:21–38. doi: 10.1016/j.antiviral.2014.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.12.015</ArticleId><ArticleId IdType="pmc">PMC5896749</ArticleId><ArticleId IdType="pubmed">25554382</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim T.M., Ismail M.I., Bauer M.R., Bekhit A.A., Boeckler F.M. Supporting SARS-CoV-2 Papain-Like Protease Drug Discovery: In silico Methods and Benchmarking. Front. Chem. 2020;8:592289. doi: 10.3389/fchem.2020.592289.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2020.592289</ArticleId><ArticleId IdType="pmc">PMC7674952</ArticleId><ArticleId IdType="pubmed">33251185</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam D., Lorenzo-Leal A.C., Hernández L.R., Bach H. Targeting SARS-CoV-2 Non-Structural Proteins. Int. J. Mol. Sci. 2023;24:13002. doi: 10.3390/ijms241613002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241613002</ArticleId><ArticleId IdType="pmc">PMC10455537</ArticleId><ArticleId IdType="pubmed">37629182</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Zeng X., Luo R., Ren S., Liang L., Huang Q., Tang Y., Fan H., Ren H., Zhang W., et al. SARS-CoV-2 NSP12 utilizes various host splicing factors for replication and splicing regulation. J. Med Virol. 2024;96:e29396. doi: 10.1002/jmv.29396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29396</ArticleId><ArticleId IdType="pubmed">38235848</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljuaid A., Salam A., Almehmadi M., Baammi S., Alshabrmi F.M., Allahyani M., Al-Zaydi K.M., Izmirly A.M., Almaghrabi S., Baothman B.K., et al. Structural Homology-Based Drug Repurposing Approach for Targeting NSP12 SARS-CoV-2. Molecules. 2022;27:7732. doi: 10.3390/molecules27227732.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27227732</ArticleId><ArticleId IdType="pmc">PMC9694939</ArticleId><ArticleId IdType="pubmed">36431833</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums D.V. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia. Med Sci. Monit. 2024;30:e944204. doi: 10.12659/MSM.944204.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.944204</ArticleId><ArticleId IdType="pmc">PMC10913280</ArticleId><ArticleId IdType="pubmed">38425279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheridan C. The world’s first CRISPR therapy is approved: Who will receive it? Nat. Biotechnol. 2023;42:3–4. doi: 10.1038/d41587-023-00016-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41587-023-00016-6</ArticleId><ArticleId IdType="pubmed">37989785</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>